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Abstract
Among the several multigene families codified by the genome of T. cruzi, the TcTASV family was the latest discovered. The
TcTASV (Trypomastigote, Alanine, Serine, Valine) family is composed of ,40 members, with conserved carboxi- and amino-
termini but with a variable central core. According to the length and sequence of the central region the family is split into 3
subfamilies. The TcTASV family is conserved in the genomes of – at least – lineages TcI and TcVI and has no orthologues in
other trypanosomatids. In the present work we focus on the study of the TcTASV-C subfamily, composed by 16 genes in the
CL Brener strain. We determined that TcTASV-C is preferentially expressed in trypomastigotes, but it is not a major
component of the parasite. Both immunoflourescence and flow cytometry experiments indicated that TcTASV-C has a clonal
expression, i.e. it is not expressed by all the parasites of a certain population at the same time. We also determined that
TcTASV-C is phosphorylated and glycosylated. TASV-C is attached to the parasite surface by a GPI anchor and is shed
spontaneously into the medium. About 30% of sera from infected hosts reacted with TcTASV-C, confirming its exposition to
the immune system. Its superficial localization and secretory nature suggest a possible role in host-parasite interactions.
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Introduction
Trypanosma cruzi is the hemoflagellate parasite that causes
Chagasdisease, also known as American Trypanosomiasis. Thir-
ty–40% of infected patients will develop a determinate form of
chronic disease (i.e., cardiac, digestive (megaoesophagus and mega
colon), or cardiodigestive). The symptoms appear generally only
20–40 years after the initial infection, when treatment is poorly
effective. [1]. Although several studies indicate that there would be
a correlation between T. cruzi lineage and clinical symptoms, no
proven associations are evident at present and both the parasite
and host genotypes are important in determining the tissue
distribution, physiopathology and eventual outcome of T. cruzi
infection [1–4]. Regardeless the clinical form, there is a consensus
that the pathology is caused by immunological imbalances that are
triggered by the parasite’s antigens [5,6]. The disease is
transmitted mostly when the parasite is in the trypomastigote
stage. In the case of vectorial transmission, the transmission is
caused by metacyclic trypomastigotes. If the infection is acquired
congenitally or through transfusions, the transmission occurs by
circulating trypomastigotes. Once inside the vertebrate host, the
trypomastigote must invade a nucleate cell, where it differentiates
to the amastigote stage and multiplies by binary fission in the
cytoplasm. After several rounds of division, amastigotes differen-
tiate again into trypomastigotes and the cell is lysed. The
trypomastigotes are released to blood and spread the infection
into the different organs/tissues, where trypomastigotes invade
other host cells, to start again the multiplication cycle [7]. During
the first months after primoinfection, circulating trypomastigotes
are easily found in blood and, if the disease is diagnosed, the
treatment is effective. The drugs that are currently available to
treat Chagas’ disease have serious side effects therefore, genes
expressed differentially in trypomastigotes are promising targets
for drug or vaccine development [1].
The completion of the sequencing of the genome of T. cruzi has
given an insight into the parasite genome, which has 3700 species-
specific genes. Several protein families have been identified
previously (trans-sialidase (TS), mucin, gp63, gp82/85, amastin,
DGF-1) or as a consequence (mucin-associated surface proteins,
MASP) of the sequencing of the T. cruzi genome [8–19] [20,21].
While some of those gene families are expressed throughout the
parasite’s life cycle, others have differential expression at a certain
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e71192
stage. Many of the genes expressed in trypomastigotes have been
associated with recognition, adhesion and/or active cell invasion
or escape of the immune response [22–33].
We have recently identified a novel family of predicted surface
proteins that was named TcTASV, due to the fact that it was first
noticed from a trypomastigote cDNA library and has a biased
composition in alanine, serine and valine [34]. In the CL Brener
strain –the first sequenced T. cruzi genome and the most
extensively annotated up to date- we found 41 TcTASV genes.
In other T. cruzi strains (RA, lineage VI and Dm28, lineage I) we
experimentally found a similar number of TcTASV genes [34];
the family is also present in the recently sequenced Sylvio strain
[35]. Interestingly, despite its broad and conserved presence in T.
cruzi strains, TcTASV has no orthologs in other trypanosomatids.
TcTASV genes have highly conserved 39UTRs, and both the
amino- and carboxi-termini of the gene products (85–100% amino
acid identity). The family is split into 3 main subfamilies (A, B and
C) according to the length and composition of the central region,
which is variable [34]. Almost all TcTASV gene products have a
predicted signal peptide and a signal for GPI anchoring, thus
suggesting that this family can be located at the parasite surface
and/or be secreted to the milieu. Bioinformatic algorithms also
predicted that TcTASVs members are phosphorylated and highly
glycosylated [34].
The TcTASV-A subfamily is composed by 21 genes in the CL
Brener strain and its expression as a ,18 kDa polypeptide in
trypomastigotes has been demonstrated in our previous work.
Peptides from 5 TcTASV-A genes were also recently identified in
the trypomastigote proteome [36]. The TcTASV-B subfamily is
composed only by 4 members in CL Brener and no genes were
detected in the Dm28 (lineage I) strain. The TcTASV-C subfamily
-composed by 16 members in the CL Brener strain, 20 in RA and
15 in Dm28- is the subfamily predicted to be more thickly
glycosylated. One member has been identified as a potential
vaccine candidate [37], but there is no data regarding its
expression. All this background information prompted us to
characterize the TcTASV-C subfamily. Briefly, we have deter-
mined that TcTASV-C is expressed mainly in the trypomastigote
stage as a ,60 kDa protein, whose carbohydrates are responsible
for at least 10 kDa of the relative molecular mass. TcTASV-C is
clonally expressed and it is not a major component of the parasite
surface. Moreover, about 30% of sera from infected hosts
recognized TcTASV-C, giving evidence of its expression during
the course of the natural infection and its contact with the immune
system of the host.
Materials and Methods
Ethics Statement
All experiments using animals were approved by the Animal
Ethical Committee of our Institution (CICUAE, Universidad
Nacional de San Martı´n) and were carried out in accordance with
national and international welfare grounds.
Parasites and antigen preparation
The parasites stocks used were CL Brener (TcVI), RA (TcVI)
and Sylvio610/7 (TcI). CL Brener and RA strains were gifts of
Dr. B. Zingales and Dr. S.M. Gonza´lez Cappa, respectively, to our
Institution [38,39]. Typing of T. cruzi evolutionary lineages was
carried out by PCR (results not shown) [40]. For in vitro assays,
parasites were obtained from axenic cultures (epimastigotes and
metacyclic trypomastigotes) or by infection of Vero cell monolay-
ers (amastigotes and released trypomastigotes) as previously
described [34]. As a rule, T. cruzi stocks are kept in liquid nitrogen
and all strains are regularly thawed once a year to preserve the
strain’s characteristics.
Essentially pure parasites of each stage were used (less than 5%
of other stages). Parasites were washed with PBS and –otherwise
indicated- lysed by incubation in a RIPA-like buffer (50 mM Tris
pH = 8, 150 mM NaCl, 1 mM Cl2Mg, 0.1% SDS, 1% NP-40,
1 mM EDTA, 1 mM DTT) plus protease inhibitor cocktail
(Sigma) and DNAseI (10 mg/ml) for 30 min on ice and clarified by
centrifugation. Proteins were quantified by Bradford and the
concentration was adjusted to 1 mg/ml. Parasite lysates were stored
–aliquoted- at 280uC until use.
Cloning, expression and purification of TASV-C
For cloning and expression of one TcTASV-C gene, nucleotides
1021 to 223 (amino acids 65 to 330) of the predicted ORF
Tcruzi_1863-4-1211-93 were amplified by PCR from the clone
G53E20 (GenBank Acc AZ050960) using Pfu DNA polymerase
and the primers CDS_int_L (ggatcctgagttggcgtcttcaag) and
CDS_int_R (tttgcactttcgtctctg). The products were cloned into
the pGEM-T Easy vector and sequenced. This internal region of
TcTASV-C was subcloned into the pGEX-3X vector (Pharmacia)
in frame with glutathione-S-tranferase (GST) to obtain the
construct TcTASV-CGST (Fig. 1). TcTASV-CGST was expressed
as a recombinant protein in E. coli BL21 and purified by standard
methodology [41].
Antisera development and IgG purification
Recombinant TcTASV-CGST was used to produce anti-
TcTASV-C serum in mice. Briefly, mice were immunized by
injection of 10 mg of TcTASV-CGST emulsified in complete
Freund’s adjuvant (1st dose) and boosted with 5 mg of TcTASV-
CGST in incomplete Freund’s adjuvant (2
nd and 3rd doses) [42].
The anti-TcTASV serum was depleted of anti-GST antibodies by
incubation with a Glutathione Sepharose 4 Fast Flow resin
(Pharmacia Biotech) coupled with 1 mg of pure GST in the
presence of protease inhibitors. The total IgG fraction of the serum
was then purified with protein G columns (HiTrap, GE
Healthcare Life Sciences). Finally, specific anti- TcTASV-C
antibodies were affinity-purified by a column coupled with the
recombinant protein (SulfoLinkH Kits; Thermo Scientific) follow-
ing the manufacturer’s instructions. The specificity of the anti-
TcTASV-C antibodies was established by competition assays (File
S1). Antibodies were used at 0.1 mg/ml for western blot and at
10 mg/ml for flow cytometry and immunofluorescence assays.
Western blot
Approximately the equivalent of 206106 trypomastigotes,
146106 epimastigotes, or 556106 amastigotes (unless otherwise
indicated) were loaded in each gel lane to assure similar protein
content among the different parasite-stages. Parasite proteins
(,20 mg/lane) were electrophoresed on 10% denaturing poly-
acrylamide gels, and transferred to nitrocellulose membranes by
standard methodologies. The membranes were blocked with PBS
–3% non-fat milk, and incubated with purified anti-TcTASV-C
antibodies (O.N., 4uC), rabbit anti-GDH antisera (1:6000, 1 h,
R.T.) or rabbit anti-TcSR62 (1:1000, 1 h, R.T.) [43,44].
Peroxidase-labeled goat anti-mouse or goat anti-rabbit (both
from Thermo Scientific) were used as secondary antibodies.
SuperSignal West Femto (when indicated) and SuperSignal West
Pico (both from Thermo Scientific) were used as chemilumines-
cent substrates to develop TcTASV-C and loading controls,
respectively.
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Enzymatic treatment of trypanosome extracts
For phosphatidylinositol-specific phospholipase C (PI-PLC)
treatment, cell-derived trypomastigotes were washed twice in
PBS and resuspended to a concentration of 108 parasites/ml in
500 ml of serum-free DMEM (Life Technologies). Parasites were
incubated for 1 h at 37uC with or without the addition of 2 U of
PI-PLC from Bacillus cereus (Sigma Aldrich). Control was
performed by incubation 56107 parasites in serum-free medium
at 0uC. The medium containing the secreted/released antigens
and the pellet containing parasites were separated by centrifuga-
tion at 4000 g for 10 min at 4uC. Secreted/released antigens and
pelleted parasites (washed twice with PBS) were processed by
western blot as described above.
The equivalent of 256106 trypomastigotes -lysed by freeze and
thaw cycles- were deglycosylated under denaturing conditions in
the presence of Triton X-100 (0.75%) at 37uC for 5 h with E-
DEGLY kit (Sigma), following the manufacturer protocol. The E-
DEGLY kit includes enzymes to remove N-linked and O-linked
carbohydrates from glycoproteins (PNGaseF, Endo-O-Glycosi-
dase, a-2(3,6,8,9)-Neuraminidase [Sialidase A], b-1,4-Galactosi-
dase and b-N-Acetylglucosaminidase).
For dephosphorylation assays, 256106 trypomastigotes were
lysed for 30 min at 4uC in a 50 mM Tris buffer (pH = 8.8)
containing 1.5 mM MgCl2, 1% TritonX-100, 1 mM DTT and
protease inhibitors, and then incubated with 15 U of calf
intestinal alkaline phosphatase (CIAP, Promega) or mock-treated
for 1 h at 37uC. The levels of deglycosylation and dephosphor-
ylation were analyzed by western blot using anti-TcTASV-C
antibodies.
Surface labeling and detection of parasites
For immunofluorescence assays, parasites resuspended at
56106/ml in PBS were layered onto 10-mm glass cover slides
pretreated with polylysine (Sigma) and fixed in 4% paraformal-
dehyde (PFA) in PBS. Cover slides were saturated in blocking
buffer (3% goat serum, 2% BSA in PBS) for 1 h, washed twice in
PBS, and incubated with either anti-TcTASV-C antibodies or IgG
purified from sera of control mice. The cover slides were washed
three times and incubated with Alexa-Fluor 488-conjugated
immunoglobulins (Molecular Probes) for 1 h at room temperature.
After the incubation with the secondary antibody, parasites were
washed, incubated with saponin (0.5%; 10 min), washed again,
and incubated either with DAPI or propidium Iodide (50 mg/ml;
15 min) for DNA stain. Finally, cover slides were mounted in
antifade reagent (FluorSave, Calbiochem), observed under a
microscope (Nikon E600) using appropriate fluorescence emission
filters, and photographed.
Labeling of parasites for flow cytometry was performed
essentially as described by Vitelli-Avelar et al., with slight
modifications [45]. In short, live trypomastigotes (106/assay) were
incubated for 1 h at 4uC with anti-TcTASV-C or control
antibodies in PBS 10% bovine fetal serum. After two washes,
parasites were incubated with Alexa-Fluor 488-conjugated goat
anti-mouse IgG (Molecular Probes, 1:1000 in PBS, 10% BFS) for
1 h on ice. Following two more washes, parasites were fixed with
FACS buffer (1% PFA, 0.01% sodium azide in PBS) and stored at
4uC in the dark [46]. Samples were acquired on a FACSCalibur
(Becton Dickinson), and data were analyzed with WinMDI 2.8
software. All experiments were carried out at least twice.
Screening of sera from infected hosts
Twenty-eight sera from T. cruzi infected rabbits and 12 non-
infected controls, from the lab’s stock were used. All the sera were
tested against T. cruzi antigens before screening the reactivity anti-
TcTASV-C. Sera proceeded from rabbits infected with RA (n = 3),
K-98 (n = 2), CA-I (n = 2), Y (n = 2), UP (n = 3), Awp (n = 3) and
Tul0 (n = 2) T. cruzi strains [47]. The infecting strains of 11 sera
were unknown.
The reactivity of sera from infected hosts was analyzed by
ELISA. Briefly, 96 wells-plates were coated with 100 ng of
recombinant TcTASV-CGST or GST per well. Sera were assayed
at 1:50, 1:100 and 1:200 dilutions and peroxidase-coupled
secondary antibodies were used at 1:10000 (goat anti-human or
goat anti-rabbit, both from Thermo Scientific). Color develop-
ment was carried out employing TMB (BD Biosciences); the
reaction was stopped with H2SO4 2N and the optical density
registered at 450 nm (OD450) (Benchmark, Microplate Reader,
BioRad). Reactivity against TcTASV-C was expressed as the
ratio of the OD450 for TASV-C and GST for a certain serum
(OD450 TcTASV-C/OD450 GST). Sera were considered positive
when the ratio was higher than the cut-off value, calculated as
the media of ratios of the non-infected sera plus 2 standard
deviations (SD).
Bioinformatic predictions
The programs NetPhos, NetOGlyc and NetNGlyc available at
the server of the Center for Biological Sequence Analysis (CBS;
Figure 1. Sequence of the protein product of Tcruzi_1863-4-1211-93, a representative member of TcTASV-C subfamily. The internal
region that was cloned to produce the recombinant protein TcTASV-CGST is underlined (amino acids 65 to 330). Amino acids that are predicted to
have post-translational modifications are highlighted. The signal peptide that is present in the N-terminal region and the consensus sequence for the
addition of a GPI anchor in the C-terminal region are both highlighted in blue (black letters). The first amino acids (white letters, highlighted in blue)
correspond to a wrong-predicted amino-terminal region.
doi:10.1371/journal.pone.0071192.g001
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http://www.cbs.dtu.dk/services/), were used to predict post-
translational modifications of proteins.
Statistical analysis
All graphics and statistical analyses were performed using the
GraphPad Prism 4.0 software. Comparison between two groups
was carried out with the Student t test.
Results
TcTASV-C is the TcTASV subfamily whose gene products are
proteins predicted to have 330-360 amino acid length. We have
previously identified TcTASV-C genes in CL Brener, RA and
Dm28 strains [34]. A posteriori, we also identified in silico the
TcTASV-C subfamily in the genomes of the Sylvio610/1 and JR
cl4 strains [35].
To study the molecular and antigenic profile of the TcTASV-C
subfamily, we selected a region spanning from Ser65 to Asn330 of
Tcruzi_1863-4-1211-93 (Fig. 1, underlined region). This region
was cloned fused to GST, expressed as recombinant protein in E.
coli and purified by affinity chromatography to glutathion agarose.
Tcruzi_1863-4-1211-93 is still annotated as an ORF at the
TriTryp database (http://TritrypDB.org), probably because it
remains as a scaffold of 1292 bp that has not been associated with
any chromosome yet (File S2) [48]. However, we had previous
evidence of its mRNA expression in trypomastigotes by northern
blot, which suggests that it is in fact a gene [34]. Moreover, we
have chosen Tcruzi_1863-4-1211-93 to work with because it has
100% identity with FN599132.1, another TASV-C gene that was
identified in the RA strain.
TcTASV-C is expressed as a ,60kDa protein, mainly in
trypomastigotes
We first analyzed the expression levels of the TcTASV-C
subfamily in different stages of T. cruzi CL Brener strain by western
blot, using purified anti-TASV-C specific antibodies (see M&M for
details and File S1 for specificity of antibodies). Development of
the assay showed a ,60 kDa band in trypomastigotes, using a
reagent that detects low femtograms of proteins (Fig. 2A). After a
longer exposure times (O.N.) an additional band of ,45 kDa was
detected in amastigotes and epimastigotes (but not in metacyclic
trypomastigotes) (Fig. 2B). As TcTASV-C genes are conserved
among different T. cruzi isolates, we then investigated if TcTASV-
C was expressed in other T. cruzi strains. TcTASV-C expression
was detected both in RA and Sylvio, but the level of protein was
variable among strains (Fig. 2C).
TcTASV-C is attached to the parasite membrane through
GPI and spontaneously shed to the medium
Given the predicted surface localization of TcTASV-C, and its
potential anchoring to the membrane through a glycosylpho-
sphatidyl inositol (GPI) anchor, we treated cell-derived trypomas-
tigotes with Phospholipase C from Bacillus cereus (PI-PLC). After
treatment, TcTASV-C-specific labeling was detected in superna-
tants, which confirms its anchoring to the membrane through GPI
(Fig. 3, upper panel). In the same assay we also tested the
spontaneous release of TcTASV-C into the medium. The
detection of TcTASV-C in the supernatants of culture medium
(Fig. 3, upper panel, PI-PLC -) indicates that this protein family is
also secreted and/or shed spontaneously from the parasite surface.
This process is due to an active secretion of TcTASV-C by
trypomastigotes because TcTASV-C was not detected in super-
natants of parasites that were incubated at 0uC. Moreover, the
detection of TcTASV-C in supernatants is not due to spontaneous
Figure 2. TcTASV-C subfamily is expressed mainly in trypo-
mastigotes, and in different T.cruzi strains. A. Western blot of total
protein extracts from CL Brener trypomastigotes (T), epimastigotes (E),
amastigotes (A) and metacyclic trypomastigotes (M) using affinity-
purified anti-TcTASV-C antibodies (upper panel). The stripped mem-
brane was tested again with anti-GDH serum to verify comparable
loading between stages (lower panel). B. A similar western as in (A) but
over exposed to evidence the expression of TcTASV-C in other T. cruzi
life stages. C. TcTASV-C expression in trypomastigotes and amastigotes
from CL Brener strain and in trypomastigotes of RA and Sylvio strains.
doi:10.1371/journal.pone.0071192.g002
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lysis of the parasites, as TcSR62, a constitutive cytoplasmic/
nucleolar T. cruzi protein, could not be detected in the same
supernatants (Fig. 3, middle panel).
TcTASV-C is phosphorylated and glycosylated in vivo
Of a total of 63 Thr, Ser and Tyr residues in the mature protein
codified by Tcruzi_1863-4-1211-93, 33 of them were predicted to
be phosphorylated (Fig. 1). Bioinformatic predictions also indicat-
ed that 19 Ser/Thr residues are putatively O-glycosylated (Fig. 1).
Similar bioinformatics predictions were found for all TcTASV-C
members. Besides, Tcruzi_1863-4-1211-93 has two predicted sites
for N-glycosylation (Fig. 1). These post-translational modifications
could alter the migration pattern of TcTASV-C in SDS-PAGE
and can help understand the differences between the expected
(36 kDa) and observed (,60 kDa) relative molecular mass of
TcTASV-C (362 aa) in western blots. We therefore treated
trypomastigotes either with CIAP to remove phosphates or a
mixture of glycosidases to remove carbohydrates from TcTASV-
C. The treatment with CIAP resulted in the migration of two
bands that were detected by western blot, which indicates that
TcTASV-C can be both in a phosphorylated and unpho-
sphorylated state (Fig. 4A). On the other hand, deglycosylation
of TcTASV-C produced a shift in the migration pattern of the
protein of ,10 kDa (Fig. 4B).
TcTASV-C is clonally expressed in the surface of
trypomastigotes
To determine the cellular localization of TcTASVs, trypomas-
tigotes were labeled by immunofluorescence using anti-TcTASV-
C antibodies (Fig. 5A–C). As can be observed in Fig. 5A, only a
minor proportion (1 out 6 in the image shown) of the parasites
were fluorescent. The labeling on positive parasites presented a
particular picture of scattered dots, both on the surface of the
parasite body and flagellum. This also indicates that TcTASV-C
family is expressed on the parasite surface since no permeabilizing
agent was used (Fig. 5B, C).
Figure 3. TcTASV-C is attached to the parasite membrane
through a GPI anchor and spontaneously shed to the medium.
Live, cell-derived CL Brener trypomastigotes were treated with 2 U of PI-
PLC at 37uC, mock-treated at 37uC or left untreated at 0uC for 1 h.
Parasites were centrifuged and both pellets (pe) and supernatants (sn)
were analyzed by western blot using purified anti-TcTASV-C antibodies
(upper panel). Trypomastigote proteins (Tryp) were also included in the
western. The membrane was stripped and re-probed with anti-TcSR62
serum to verify whether there had been spontaneous lysis of the
parasites (middle panel). The total protein transferred in each line is
shown by Poinceau S staining (lower panel).
doi:10.1371/journal.pone.0071192.g003
Figure 4. TcTASV-C is phosphorylated and glycosylated. Lysates
of T. cruzi trypomastigotes were treated with CIAP (A) or glycosidases
(B), electrophoresed on a 12% SDS-PAGE gel, transferred to nitro-
cellulose membrane and TcTASV-C detected using anti-TcTASV-C
antibodies.
doi:10.1371/journal.pone.0071192.g004
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To verify the predicted location of TcTASV-C and immuno-
flourescence results, we labeled live RA and CL Brener
trypomastigotes with anti-TcTASV-C antibodies, and then
analyzed them by flow cytometry. As shown in Figure 5D–E,
TcTASV-C was detected on the surface of trypomastigotes in both
T. cruzi strains. Only 57.5% (CL Brener, Fig. 5D) and 24.4% (RA,
Fig. 5E) of the parasites were FITC positive, which indicates that
not every trypomastigote expresses TcTASV-C on their surface at
the same time. These results also show that TcTASV-C is
expressed in a greater number of cells in CL Brener than in RA
strain, which is in agreement with our previous western blot
results. Besides, most positive events showed moderate fluores-
cence intensity, indicating that TcTASV-C is expressed at a
moderate level. To confirm the specificity of binding, TcTASV-C
antibodies that had been previously pre-adsorbed with the
recombinant protein TcTASV-CGST were also incubated with
trypomastigotes, in which case no differences were observed with
the labeling obtained by pre-immune antibodies (Fig. 5D–E, green
line: pre-adsorbed; black line: IgG from control mice).
TcTASV-C is recognized by sera of infected hosts
To further characterize TcTASV-C, we evaluated its capacity
to induce specific antibodies in T. cruzi infected hosts. Sera from
rabbits infected with different T. cruzi lineages were assayed by
ELISA to evaluate their reactivity against TcTASV-CGST. The
mean reactivity -measured as the average of optical densities (ODs)
of sera against TcTASV-CGST- was higher in infected than in non-
infected animals (infected: 0.557960.35; non-infected:
0.229860.10; p = 0.0005). The average reactivity of the same
group of sera against GST, the protein used as background
control, was similar in both groups (infected: 0.241960.13; non-
infected: 0.178460.11; p = n.s.) (Fig. 6A). These differences in the
mean values did not reflect the fact that –among T. cruzi infected
rabbits- some sera were reactive to TcTASV-C and some others
Figure 5. TcTASV-c is expressed at the trypomastigote surface. A–C: Indirect immunofluorescence was performed on unpermeabilized
trypomastigotes using anti-TcTASV-C antibodies. Asterisks in A denote parasites that do not express TcTASV-C, whose DNA content was labeled with
DAPI. B and C: Magnification showing the surface pattern of the TcTASV-C distribution. DNA labeling: A and B: DAPI; C: propidium iodide (PI). D–E:
Live trypomastigotes (16106/assay) from CL Brener (D) or RA (E) strains were reacted with affinity-purified anti-TcTASV-C antibodies (blue) for 1 hour
at 4uC and processed for analysis by flow cytometry. The specificity of the binding to TcTASV-C proteins was confirmed by pre-adsorption of the
antibodies with the recombinant protein TcTASV-C before incubation with the parasites (pre-adsorbed, green line). Negative (IgG from normal mice;
black line) and positive (sera from T. cruzi-infected mice; purple line) controls were included.
doi:10.1371/journal.pone.0071192.g005
TcTASV-C Is at Trypomastigote Surface in T. cruzi
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e71192
were not. To distinguish which individual sera were those
specifically reacting with TcTASV-C, we calculated the ratio of
the OD values obtained for each serum against TASV-CGST and
GST (Fig. 6B). Ten out of 28 sera (35.71%) of infected rabbits
reacted with TcTASV-C. However, with these serum samples we
could not see any correlation between reactivity to TcTASV-C
and lineage of the T. cruzi infecting strain (File S3). In a murine
model of T. cruzi infection, anti-TcTASV-C antibodies were
detected starting from 20 days post-infection. This finding was
coincident with the peak of circulating trypomastigotes, and the
acute phase of infection (File S4). We also evaluated the reactivity
of a panel of 42 human sera (30 positive and 12 negative, as
indicated by anti-T. cruzi serology) provided by the serum bank of
the Instituto Nacional de Parasitologı´a ‘‘Dr. Mario Fatala
Chaben’’ (Ministerio de Salud, ANLIS, Buenos Aires, Argentina).
As observed for rabbit’s sera, the mean reactivity of infected
people against TcTASV-CGST was higher than controls (infected:
0.328060.13; non-infected: 0.196660.05; p = 0.0005), while no
differences were found in the reactivity against GST between both
groups (Fig. 6C). Ten sera from infected individuals (33%) were
reactive to TcTASV-C, as calculated by the TcTASV-C/GST
ratio (Fig. 6D). This result is particularly relevant because it
indicates that TcTASV-C is antigenic in the natural infection, not
only in an experimental model of the disease but also in the
natural cell cycle involving humans.
Discussion
Most of the works about multigene families in T. cruzi that were
carried out before the completion of the T. cruzi genome studied
highly expressed proteins (mucins, trans-sialidase, cruzipain,
amastin, amongst others) [13,18,49,50]. On the other hand, the
multigene family MASP was discovered when the parasite’s
genome was sequenced and annotated, and is a good example of
how a genome project shed light into the structure of a genome
[11,17,51]. Although the MASP family is composed by a very
large number of genes (.1400), the delay in its identification was
probably due to its unusual or not-so-abundant protein expression
pattern. Therefore, it is no surprise that the TcTASV gene family
–composed by a much lower number of genes- was not noticed
even after the completion of the sequencing of the T. cruzi genome.
Several years ago, we started a project to identify genes
expressed preferentially in the different stages of T. cruzi by means
of ESTs sequencing [34,52,53]. The analysis of an epimastigote-
substracted trypomastigote cDNA library led us to the identifica-
tion of a novel gene family, named TcTASV [34]. In the early
versions of the T. cruzi database (TcruziDB and TriTrypDB 1.0–
2.3) some TcTASVs genes were annotated as hypothetical or
mucin-like genes, while others were solely marked as open reading
frames [54]. In our previous work we demonstrated that TcTASV
was indeed a novel gene family, conserved among different T. cruzi
lineages and with no orthologs in other species (including
trypanosomatids). Added to these characteristics, the TcTASV
family turns out to be an attractive target for study since a
TcTASV-C gene was identified among a pool of protective
vaccine antigens [37].
Here we demonstrate that TcTASV-C proteins are expressed in
Trypanosoma cruzi, mainly in the trypomastigote stage. We also
found that TcTASV-C is localized at the cellular surface,
anchored to the membrane through a GPI moiety and released
spontaneously to the milieu. We also determined that TcTASV-C
is not a major component of the parasite surface. The detection of
TcTASV-C by western blot was achieved by using a reagent that
detects low femtograms of protein in the equivalent of ,206106
trypomastigotes. This was also supported by flow cytometry and
immunofluorescence experiments, where few labeled parasites
were observed among the whole population. Both western blot
and flow cytometry data also showed that the expression of
TcTASV-C is variable among different T. cruzi strains, being
much more abundant in CL Brener than RA, despite the fact that
both strains belong to the same lineage. In T. brucei, several minor
components of the cell surface turned out to have important
functions in maturation of infection [55,56]. In that sense, Fragoso
et al. (2009) [55] demonstrated that the phosphoprotein PSSA-2 is
essential to colonize the salivary glands of the tse-tse fly and to
produce metacyclic forms. Moreover, the correct localization and
function of this protein in the plasma membrane is dependent on
the phosphorylation of a cytoplasmic residue of threonine.
We have also demonstrated here that TcTASV-C expression
follows a clonal expression pattern, i.e. in a certain parasite
population the expression of this subfamily is not uniform. This is
particularly interesting since it opens an additional question about
the regulation mechanism of expression of surface proteins in T.
cruzi. Protein translation in trypanosomatids is tightly regulated by
the interaction of cis-acting elements (mainly the 39 UTR of the
genes) and RNA binding proteins [57]. In the case of the
TcTASV-C family, the 39UTR is highly conserved, and is actually
a ‘hallmark’’ of the gene family. A similar situation has been
recently described for masp genes [51]; in their work, dos Santos
et al. (2012) suggested that subtle nucleotide differences in the
39UTR regions can alter the interaction with regulatory proteins
that favor or prevent the translation of specific transcripts.
However, this hypothesis does not explain why the expression of
a protein (in our case TcTASV-C) is silenced in some parasites but
active in others. Recent findings indicate the existence of the base J
and epigenetic regulation of gene expression in T. cruzi [58,59]. In
T. brucei, epigenetic modifications are involved in the control of
antigenic variation [60,61], which suggest this kind of regulation
for the TcTASV family as a possibility to be studied.
Another interesting characteristic of the expression pattern of
TcTASV-C is its distribution on the parasite membrane as dots
(patches) that resemble detergent resistant membrane domains
(DRMs). Some proteins that are phosphorylated and anchored to
the plasma membrane by GPI can be localized in lipid rafts. This
has been demonstrated in T. brucei for PARB, which is present in
small discrete spots distributed over the entire cellular surface [62].
TcTASV-C presents these characteristics, and even though we did
not assay if TcTASV-C is associated to DRMs, this could be a
possibility. Nevertheless and as mentioned above, the phosphor-
ylation of a protein can alter its behavior in a wide range from
function, signal transduction or subcellular localization, among
others. In T. brucei, the differential phosphorylation state of the
procyclins EP and GPEET (two GPI-anchored proteins) is
coordinated and changes through the life cycle of the parasite.
Indeed, the phosphorylation/dephosphorylation state has been
linked to the membrane localization (flagellar pocket vs. cell
surface) [63]. In our case, we have detected the expression of
TcTASV-C by western blot both in trypomastigotes and, although
in a much lower level, in epimastigotes and amastigotes. However,
and in contrast to findings in trypomastigotes, we failed to detect
the expression of TcTASV-C at the cellular surface in non-
permeabilized epimastigotes (data not shown). This could reflect a
differential phosphorylation state in TcTASV-C in both parasite
stages that might regulate its localization and eventually its
activity.
Although we have found that the TcTASV-C subfamily is
expressed in trypomastigotes, no TcTASV-C peptides were
identified in the trypomastigote proteome [36]. We also deter-
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mined here that TcTASV-C is glycosylated and is anchored to the
membrane through a GPI anchor. In the work of Nakayasu et al
(2012), trypomastigotes were lysed by sonication, which does not
favor the extraction of membrane-bound proteins. Moreover,
some highly glycosylated proteins (like TcTASV-C) cannot be
digested correctly by standard methodologies, which also can
explain its non-detection in MS-MS analysis. On the other hand, 5
TcTASV-A genes were identified in the trypomastigote proteome,
in agreement to our evidences of the intracellular localization of
TcTASV-A in trypomastigotes (unpublished observations). The
proteomes of metacyclic trypomastigotes and epimastigotes –
designed to preferentially identify membrane-bound and/or
hydrophobic proteins- failed to find any TcTASV peptide [64],
in line with results presented here that showed a minimum
expression (or absence) of TcTASV-C in insect-derived parasite-
stages.
The reactivity to the recombinant TcTASV-C displayed by sera
from animals and humans infected with T. cruzi demonstrated the in
vivo expression of TcTASV-C and its contact with the immune
system of the host. Furthermore, the heterogeneous reactivity
(detected in ,30% of sera both in natural and experimental
infections) remained elusive any possible association with the
Figure 6. TcTASV-C is recognized by sera from infected hosts. The reactivity of sera from rabbits (A, B) and humans (C, D) against TcTASV-C
(and GST) was evaluated by ELISA. Results are presented as absorbance at 450 nm (A, C) or as the ratio between the ODs obtained for each
serum against TcTASV-C and GST (B, D). Asterisks in A and C denote differences in the mean values (p,0.005). Dotted lines in B and D represent
the cut-off, calculated as the mean + 2SD of control (uninfected) sera. Human’s sera: infected: N = 30; uninfected: N = 12. Rabbit’s sera: infected: 28;
uninfected: 12.
doi:10.1371/journal.pone.0071192.g006
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infecting strain or status of the infection (i.e. acute vs chronic), and
also reflects the complex humoral response elicited by T. cruzi
infection. Future studies will be necessary to determine if TcTASV-
C reactivity can be a predictor of disease evolution, since the
percentage of reactivity observed is quite similar to those of the
patients that develop symptoms at the chronic phase of the disease.
In brief, we have demonstrated here that TcTASV-C is a novel
protein family in T. cruzi expressed on the surface of trypomas-
tigotes. TcTASV-C is phosphorylated, heavily glycosylated, shed
to the medium and is in contact with the immune system of the
host during the course of the natural infection. All these
characteristics are particularly interesting since the trypomastigote
is the parasite stage that circulates in blood and disseminates the
infection to secondary organs by invasion of novel cells. Future
work is needed to determine the function of TcTASV-C, but our
current hypotheses include both its putative involvement in
immune evasion and host-parasite interactions.
Supporting Information
File S1 Specificity analysis of anti-TcTASV-C antibodies
by competition assays. Total protein extracts from CL Brener
trypomastigotes (T), epimastigotes (E) and amastigotes (A) were
electrophoresed on 10% acrylamide gels and transferred onto
nitrocellulose membranes. After blocking with PBS containing 3%
non-fat milk, membranes were probed with affinity-purified anti-
TcTASV-C antibodies that had been pre-adsorbed with recom-
binant TcTASV-CGST (left panel), recombinant TcTASV-BGST
(middle panel) or left untreated (right panel). IgG pre-adsorption
was carried out by incubating the antibody solution with the
recombinant proteins at 0.5 mg/ml for 1 h at 4uC. Development
was carried out as indicated in the Materials and Methods section.
The stripped membrane was tested again with anti-GDH serum to
verify comparable loading between stages (lower panel).
(JPG)
File S2 Genes and ORFs of the TcTASV family. The
TriTrypDB was searched to identify all the genes and open
reading frames (ORFs) from CL Brener strain that belong to the
TcTASV family. The subfamilies are clearly indicated.
(XLS)
File S3 Reactivity against TcTASV-C is not associated
with T. cruzi infecting strain. The reactivity of individual sera
from T. cruzi infected rabbits is plotted showing the T. cruzi strain
that infected each animal.
(PDF)
File S4 Follow up of parasitemia and anti-TcTASV-C
antibodies in an experimental murine model of T. cruzi
infection. Mice (n = 4) were infected with 100 trypomastigotes of
the RA strain (TcVI). The levels of circulating parasites and anti-
TcTASV-C antibodies (ELISA) were monitored during the course
of infection. The graphs show parasitemia (trypomastigotes/ml)
and anti-TcTASV-C reactivity (OD at 450 nm), both expressed as
mean 6 SD (upper panel) and the anti-TcTASV-C reactivity of
the individual mice during the course of infection (lower panel).
(PDF)
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